On Tuesday, Shares of AstraZeneca plc (ADR)(NYSE:AZN), subtract -2.93% and closed at $31.12 in the last trading session. The last trading range of the stock ranges between $31.05 and $31.69. The company’s Market capitalization is $77.24 Billion with the total Outstanding Shares of 1.26 billion. During the 52-week trading session the minimum price at which share price traded, registered at $26.97 and reached to max level of $35.04. AstraZeneca recently declared data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for fulvestrant 500mg contrast to anastrozole 1mg in the 1st line treatment of postmenopausal women with locally-advanced or metastatic breast cancer, who have not had prior hormonal treatment for hormone receptor positive (HR+) breast cancer.1 The primary endpoint was PFS and the FALCON trial enrolled 462 patients.
The results, declared at the 2016 European Society for Medical Oncology (ESMO) Congress, show that the median PFS was 2.8 months longer with fulvestrant than anastrozole (Hazard ratio 0.797; 95% confidence interval: 0.637-0.999; p=0.0486). The median PFS was 16.6 months in the fulvestrant arm, contrast with 13.8 months in the anastrozole arm.1 Aromatase inhibitors, such as anastrozole, are the current standard of care in 1st line treatment for postmenopausal women with hormone-receptor positive (HR+) advanced breast cancer. 2,3,4
Professor Matthew Ellis, Principal Investigator of the FALCON trial, said: “These data document a benefit for fulvestrant in delaying disease progression as a 1st line therapy, an important aim for women with metastatic breast cancer. The results are supported by a previous trial, which also showed an advantage for fulvestrant over anastrozole. The results are clinically meaningful and suggest that fulvestrant could be used as 1st line therapy for women with advanced breast cancer.”
Gap Inc (NYSE:GPS), jumped 0.53% and closed at $26.56 in the last trading session. The last trading range of the stock ranges between $26.26 and $26.77. During the 52-week trading session the minimum price at which share price traded, registered at $17.00 and reached to max level of $30.49. In celebration of International Day of the Girl, Gap Inc. recently declared the expansion of its signature education program, P.A.C.E. (Personal Advancement & Career Enhancement), with new curriculum designed to improve confidence and life skills for girls in community settings. To coincide with this declarement, the company’s namesake brand partnered with Condé Nast to showcase the inspirational stories of women who are presently participating in P.A.C.E.
At the center of Gap and Condé Nast’s partnership is a 12-minute documentary-style film profiling the stories of three unique women – Mary, Margaret and Puwaneshwary – who are presently enrolled in a P.A.C.E. community program. The film shines a light on how access to education has changed the lives of these women who work on a tea plantation in Sri Lanka, where literacy rates for women are typically very low – 67 percent contrast to the country’s average of 90 percent (source:CARE Sri Lanka).
Created by the award-winning 23 Stories x Condé Nast studio and directed by internationally acclaimed filmmaker Vanessa Black, the documentary premiers on Vogue’s digital channels in both the U.S. and the U.K. starting recently.
On the otherhand AngloGold Ashanti Limited (ADR)(NYSE:AU), lost -3.50% and closed at $12.96 in the last trading session. The last trading range of the stock ranges between $12.96 and $13.31. The company’s Market capitalization is $5.25 billion with the total Outstanding Shares of 408.20 million. During the 52-week trading session the minimum price at which share price traded, registered at $6.20 and reached to max level of $22.91. AngloGold Ashanti Limited operates as a gold mining and exploration company. The company also produces silver, uranium oxide, copper, and sulphuric acid. Its portfolio includes 17 mines in South Africa, Continental Africa, Australasia, and the Americas.